"Moderna's Unexpected Profit and RSV Vaccine Roadmap"
TL;DR
Moderna surprised with a fourth-quarter profit, attributing it to cost cutting and deferred payments, while also outlining plans for its experimental RSV vaccine. The company reported a decline in COVID-19 vaccine sales but expects a U.S. approval decision for its RSV shot by May 12. Moderna also anticipates data from late-stage trials of its next generation COVID shot and other combination vaccines this year, reaffirming its 2024 sales forecast despite a projected revenue decrease.
Topics:top-newsbusiness-healthcare#business-healthcare#covid-19#moderna#profit#rsv-vaccine#vaccine-development
- Moderna reports surprise profit, sets out road map for RSV vaccine Yahoo Finance
- Moderna posts surprise quarterly profit even as Covid vaccines sales plummet CNBC
- Moderna posts surprise quarterly profit even as COVID sales continue to slide MarketWatch
- Moderna Stock Jumps on Surprise Profit, Sales Ahead of Expectations Barron's
- Moderna: Q4 Earnings Snapshot Quartz
Want the full story? Read the original reporting
Read on Yahoo Finance